Suppr超能文献

用于前列腺癌近距离治疗的(125)I眼-前列腺籽源的生物评估

Bioevaluation of (125) I Ocu-Prosta seeds for application in prostate cancer brachytherapy.

作者信息

Mukherjee Archana, Sarma Haladhar Dev, Saxena Sanjay, Kumar Yogendra, Chaudhari Pradip, Goda Jayant Sastri, Adurkar Pranjal, Dash Ashutosh, Samuel Grace

机构信息

Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India.

出版信息

Indian J Med Res. 2014 Apr;139(4):555-60.

Abstract

BACKGROUND & OBJECTIVES: In recent years, brachytherapy involving permanent radioactive seed implantation has emerged as an effective modality for the management of cancer of prostate. 125 I-Ocu-Prosta seeds were indigenously developed and studies were carried out to assess the safety of the indigenously developed 125 I-Ocu-Prosta seeds for treatment of prostate cancer.

METHODS

Animal experiments were performed to assess the likelihood of in vivo release of 125 I from radioactive seeds and migration of seeds implanted in the prostate gland of the rabbit. In vivo release of 125 I activity was monitored by serial blood sampling from the auricular vein and subsequent measurement of 125 I activity. Serial computed tomography (CT) scans were done at regular intervals till 6 months post implant to assess the physical migration of the seeds.

RESULTS

The laser welded seeds maintained their hermeticity and prevented the in vivo release of 125 I activity into the blood as no radioactivity was detected during follow up blood measurements. Our study showed that the miniature 125 I seeds were clearly resolved in CT images. Seeds remained within the prostate gland during the entire study period. Moreover, the seed displacement was minimal even within the prostate gland.

INTERPRETATION & CONCLUSIONS: Our findings have demonstrated that indigenously developed 125 I-Ocu-Prosta seeds may be suitable for application in treatment of prostate cancer.

摘要

背景与目的

近年来,永久性放射性粒子植入近距离放射治疗已成为前列腺癌治疗的一种有效方式。国产125I - Ocu - Prosta粒子已研发成功,并开展了相关研究以评估其用于治疗前列腺癌的安全性。

方法

进行动物实验,以评估放射性粒子中125I在体内的释放可能性以及植入兔前列腺内的粒子迁移情况。通过从耳静脉连续采血并随后测量125I活性来监测125I活性的体内释放。在植入后定期进行连续计算机断层扫描(CT),直至植入后6个月,以评估粒子的物理迁移情况。

结果

激光焊接的粒子保持了密封性,且由于在后续血液测量中未检测到放射性,故可防止125I活性在体内释放到血液中。我们的研究表明,微型125I粒子在CT图像中清晰可辨。在整个研究期间,粒子均保留在前列腺内。此外,即使在前列腺内,粒子的移位也极小。

解读与结论

我们的研究结果表明,国产125I - Ocu - Prosta粒子可能适用于前列腺癌的治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68a0/4078493/a15d9a05dc50/IJMR-139-555-g002.jpg

相似文献

本文引用的文献

2
Brachytherapy for prostate cancer: a systematic review.前列腺癌近距离治疗:一项系统评价
Adv Urol. 2009;2009:327945. doi: 10.1155/2009/327945. Epub 2009 Sep 1.
4
Current status and perspectives of brachytherapy for prostate cancer.前列腺癌近距离治疗的现状与展望
Int J Clin Oncol. 2009 Feb;14(1):31-6. doi: 10.1007/s10147-008-0866-z. Epub 2009 Feb 20.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验